BRPI0819719B8 - compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo - Google Patents

compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Info

Publication number
BRPI0819719B8
BRPI0819719B8 BRPI0819719A BRPI0819719A BRPI0819719B8 BR PI0819719 B8 BRPI0819719 B8 BR PI0819719B8 BR PI0819719 A BRPI0819719 A BR PI0819719A BR PI0819719 A BRPI0819719 A BR PI0819719A BR PI0819719 B8 BRPI0819719 B8 BR PI0819719B8
Authority
BR
Brazil
Prior art keywords
methods
active agent
dipeptidyl peptidase
pharmaceutical preparations
preparations containing
Prior art date
Application number
BRPI0819719A
Other languages
English (en)
Inventor
Lee Chang-Seok
Min Changhee
Bong Lee Hee
Joo Yim Hyeon
Lee Jaeick
Kim Kyoung-Hee
Woong Lee Kyu
Lee Sung-Hack
Su Park Wan
Original Assignee
Lg Chemical Ltd
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd, Lg Life Sciences Ltd filed Critical Lg Chemical Ltd
Publication of BRPI0819719A2 publication Critical patent/BRPI0819719A2/pt
Publication of BRPI0819719A8 publication Critical patent/BRPI0819719A8/pt
Publication of BRPI0819719B1 publication Critical patent/BRPI0819719B1/pt
Publication of BRPI0819719B8 publication Critical patent/BRPI0819719B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo. novos compostos de fórmula (1) são descritos aqui como definidos na especificação dotados de excelente atividade inibitória contra dipeptidil peptidase-iv (dpp-v), métodos de preparação dos mesmos e composições farmacêuticas compreendendo os mesmos como um agente ativo.
BRPI0819719A 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo BRPI0819719B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070134887 2007-12-21
KR10-2007-0134887 2007-12-21
PCT/KR2008/007543 WO2009082134A2 (en) 2007-12-21 2008-12-19 Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent

Publications (4)

Publication Number Publication Date
BRPI0819719A2 BRPI0819719A2 (pt) 2015-06-16
BRPI0819719A8 BRPI0819719A8 (pt) 2015-09-22
BRPI0819719B1 BRPI0819719B1 (pt) 2020-09-24
BRPI0819719B8 true BRPI0819719B8 (pt) 2021-05-25

Family

ID=40801676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819719A BRPI0819719B8 (pt) 2007-12-21 2008-12-19 compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo

Country Status (14)

Country Link
US (1) US8470836B2 (pt)
EP (1) EP2220086A4 (pt)
JP (1) JP5358585B2 (pt)
KR (1) KR101105607B1 (pt)
CN (1) CN101903386B (pt)
AU (1) AU2008341352B2 (pt)
BR (1) BRPI0819719B8 (pt)
CA (1) CA2710109C (pt)
CO (1) CO6300861A2 (pt)
EA (1) EA201070635A1 (pt)
MA (1) MA31919B1 (pt)
UA (1) UA103181C2 (pt)
WO (1) WO2009082134A2 (pt)
ZA (1) ZA201004214B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5705985B2 (ja) * 2010-09-03 2015-04-22 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 医薬品合成用中間体化合物の製造方法
CN102617566B (zh) * 2011-01-30 2015-03-04 山东轩竹医药科技有限公司 吡啶并咪唑烷衍生物
CN102875567B (zh) * 2011-07-15 2015-03-11 天津药物研究院 一类含哌嗪化合物、制备及用途
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY168411A (en) * 2012-02-03 2018-11-09 Lg Chemical Ltd Method for preparing compound by novel michael addition reaction using water or various acids as additive
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
CN105017244A (zh) * 2014-04-16 2015-11-04 上海药明康德新药开发有限公司 顺反叔丁基-4-氧六氢化-1H-吡咯[3,4-c]吡啶-2(3H)-羧酸叔丁酯的合成方法
CN104447511A (zh) * 2014-11-12 2015-03-25 江苏中邦制药有限公司 一种n-叔丁氧羰基-3-哌啶酮的合成方法
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
KR102184129B1 (ko) * 2017-11-16 2020-11-27 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
DE60316416T2 (de) 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
JP4564952B2 (ja) 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
WO2004089362A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S 2-cyanopyrroles and their analogues as ddp-iv inhibitors
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth

Also Published As

Publication number Publication date
KR20090068156A (ko) 2009-06-25
CA2710109A1 (en) 2009-07-02
CN101903386B (zh) 2015-04-22
US8470836B2 (en) 2013-06-25
CO6300861A2 (es) 2011-07-21
EP2220086A2 (en) 2010-08-25
JP5358585B2 (ja) 2013-12-04
CN101903386A (zh) 2010-12-01
ZA201004214B (en) 2011-04-28
KR101105607B1 (ko) 2012-01-18
UA103181C2 (ru) 2013-09-25
US20100274013A1 (en) 2010-10-28
EP2220086A4 (en) 2010-12-22
EA201070635A1 (ru) 2010-12-30
AU2008341352B2 (en) 2013-08-01
WO2009082134A3 (en) 2009-09-24
BRPI0819719A8 (pt) 2015-09-22
AU2008341352A1 (en) 2009-07-02
BRPI0819719A2 (pt) 2015-06-16
CA2710109C (en) 2016-07-19
JP2011507832A (ja) 2011-03-10
MA31919B1 (fr) 2010-12-01
BRPI0819719B1 (pt) 2020-09-24
WO2009082134A2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
BRPI0819719B8 (pt) compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
GEP20125469B (en) Inhibitors of akt activity
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
MX336381B (es) Boronatos como inhibidores de arginasa.
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
NI200700064A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos.
MX2009010047A (es) Compuestos quimicos.
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MX2009010045A (es) Compuestos quimicos.
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
BR112012015755A8 (pt) lipídeos, composições de lipídeos, e métodos de uso dos mesmos
BRPI1006115A8 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
JO2770B1 (en) Organic compounds
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
WO2005075471A3 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF